Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Benefits Of Avandia, Actos Outweigh Risks – EMEA

This article was originally published in The Pink Sheet Daily

Executive Summary

EMEA panel recommends additional warnings for rosiglitazone products, but gives positive opinion on continued marketing.

You may also be interested in...



Avandia Monotherapy Use Curtailed in Canada

Cardiac safety concerns fuel Health Canada to recommend rosiglitazone as second-line treatment for diabetes.

Avandia Monotherapy Use Curtailed in Canada

Cardiac safety concerns fuel Health Canada to recommend rosiglitazone as second-line treatment for diabetes.

BART Sends Bayer’s Trasylol Off The Market

Bayer “temporarily” phases out proteinase inhibitor after top-line data show 50% higher death rate for Trasylol versus comparators.

Related Content

Topics

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel